<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925843</url>
  </required_header>
  <id_info>
    <org_study_id>19.115</org_study_id>
    <nct_id>NCT04925843</nct_id>
  </id_info>
  <brief_title>Fibrinogen and Intraoperative Bleeding in Liver Transplant</brief_title>
  <acronym>FIB_TOF</acronym>
  <official_title>Association Between Fibrinogen Concentration and Intraoperative Bleeding in Liver Transplantation: a Retrospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hopital Paul Brousse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver transplantation is the only treatment for end-stage liver disease. It is a high-risk&#xD;
      surgery that can cause heavy intraoperative bleeding. Bleeding and transfusions of blood&#xD;
      products are themselves associated with several postoperative complications. Few data have&#xD;
      suggested beneficial interventions that can decrease this bleeding. Such interventions are&#xD;
      necessary in order to improve these patients' outcomes. In order to better understand the&#xD;
      potential therapeutic targets, a better comprehension of the variables associated with such&#xD;
      bleeding is essential. Several previous studies have demonstrated a weak association between&#xD;
      usual clotting times and bleeding in this population. However, few studies have evaluated the&#xD;
      association between the concentration of fibrinogen and bleeding in this population.&#xD;
&#xD;
      The primary objective of this study is to assess the association between preoperative serum&#xD;
      fibrinogen concentration and the volume of intraoperative bleeding. The secondary objective&#xD;
      is to assess the association between preoperative serum fibrinogen concentration and the&#xD;
      number of red blood cell units transfused during the intraoperative and immediate&#xD;
      postoperative periods.&#xD;
&#xD;
      The hypothesis of the study is that a low concentration of preoperative fibrinogen will be&#xD;
      associated with an increase in intraoperative bleeding and red blood cell transfusions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients who received a liver transplant between July 2008 and December 2020 at the&#xD;
      Centre Hospitalier de l'Université de Montréal (CHUM) and the hepato-biliary center of the&#xD;
      Paul-Brousse Hospital between January 2017 and December 2020 will be included. The effect of&#xD;
      fibrinogen concentration, intraoperative bleeding, intraoperative and postoperative&#xD;
      transfusions, as well as postoperative bleeding-related complications and mortality up to 1&#xD;
      year will be assessed. The analysis will be adjusted for several confounding factors,&#xD;
      including other coagulation parameters. The main association model will be a multivariable&#xD;
      linear regression.&#xD;
&#xD;
      This study will be used to further explore the association between fibrinogen concentration&#xD;
      and bleeding in liver transplantation. These results may help certain clinical decisions,&#xD;
      without suggesting any potential effect of fibrinogen correction on clinical outcomes. If an&#xD;
      association is found, the bases will be put in place to build a clinical trial evaluating the&#xD;
      effects of a preemptive transfusion of blood products correcting this value on clinical&#xD;
      outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated blood loss per mass of red blood cells lost</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>In milliliters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of red blood cell transfusions during liver transplantation</measure>
    <time_frame>At the end of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of perioperative red blood cell transfusions</measure>
    <time_frame>From the beginning of surgery until 48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of bleeding complications leading to reintervention and / or angioembolization</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of early retransplantation</measure>
    <time_frame>30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year survival</measure>
    <time_frame>One year after surgery</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>End Stage Liver DIsease</condition>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Patients undergoing liver transplant for end-stage liver disease</arm_group_label>
    <description>The investigators propose to conduct a retrospective cohort study to explore the association between fibrinogen concentration and intraoperative bleeding in patients who underwent a liver transplant between July 2008 and December 2020.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who underwent a liver transplant for a chronic liver disease during the&#xD;
        reference period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients undergoing liver transplant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of cryoprecipitate or fresh frozen plasma after measurement of serum fibrinogen&#xD;
             concentration prior to arrival in the operating room.&#xD;
&#xD;
          -  Amyloid neuropathy.&#xD;
&#xD;
          -  Fulminant hepatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Martin Carrier, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François Martin Carrier, MD, MSc</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>12132</phone_ext>
    <email>fm_carrier@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monique Ruel, RN</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>12171</phone_ext>
    <email>monique.m.ruel.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Ruel, RN</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>12171</phone_ext>
      <email>monique.m.ruel.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie Desroches, PhD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>12172</phone_ext>
      <email>julie.desroches.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Annie Deshêtres, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michaël Chassé, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Rioux-Massé, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Massicotte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Martin Carrier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Paul-Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Joosten, MD</last_name>
      <email>joosten-alexandre@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

